A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

NCT02804763 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: Placebo
DRUG: Dapirolizumab pegol (DZP)

Sponsor

UCB Biopharma S.P.R.L.